Mostrar el registro sencillo del ítem
Artículo
Clinical characteristics and outcome of drug-induced liver injury in the older patients: from the young-old to the oldest-old
dc.creator | Weersink, Rianne A. | es |
dc.creator | Alvarez-Alvarez, Ismael | es |
dc.creator | Medina-Cáliz, Inmaculada | es |
dc.creator | Romero Gómez, Manuel | es |
dc.creator | Ampuero Herrojo, Javier | es |
dc.creator | Rodríguez Seguel, Elisa del Pilar | es |
dc.creator | Cuevas, L. | es |
dc.date.accessioned | 2022-10-27T16:51:01Z | |
dc.date.available | 2022-10-27T16:51:01Z | |
dc.date.issued | 2021 | |
dc.identifier.citation | Weersink, R.A., Alvarez-Alvarez, I., Medina-Cáliz, I., Romero Gómez, M., Ampuero Herrojo, J., Rodríguez Seguel, E.d.P. y Cuevas, L. (2021). Clinical characteristics and outcome of drug-induced liver injury in the older patients: from the young-old to the oldest-old. Clinical Pharmacology & Therapeutics, 109 (4), 1147-1158. https://doi.org/10.1002/cpt.2108. | |
dc.identifier.issn | 1532-6535 | es |
dc.identifier.issn | 0009--9236 | es |
dc.identifier.uri | https://hdl.handle.net/11441/138440 | |
dc.description.abstract | Older patients with hepatotoxicity have been scarcely studied in idiosyncratic drug-induced liver injury (DILI) cohorts. We sought the distinctive characteristics of DILI in older patients across age groups. A total of 882 DILI patients included in the Spanish DILI Registry (33% ≥ 65 years) were categorized according to age: “young” (< 65 years); “young-old” (65–74 years); “middle-old” (75–84 years); and “oldest-old” (≥ 85 years). All elderly groups had an increasingly higher comorbidity burden (P < 0.001) and polypharmacy (P < 0.001). There was a relationship between jaundice and hospitalization (P < 0.001), and both were more prevalent in the older age groups, especially in the oldest-old (88% and 69%, respectively), and the DILI episode was more severe (P = 0.029). The proportion of females decreased across age groups from the young to the middle-old, yet in the oldest-old there was a distinct female predominance. Pattern of liver injury shifted towards cholestatic with increasing age among top culprit drugs amoxicillin-clavulanate, atorvastatin, levofloxacin, ibuprofen, and ticlopidine. The best cutoff point for increased odds of cholestatic DILI was 65 years. Older patients had increased non–liver-related mortality (P = 0.030) as shown by the predictive capacity of the Model for End-Stage Liver Disease score (odds ratio (OR) = 1.116; P < 0.001), and comorbidity burden (OR = 4.188; P = 0.001) in the 6-month mortality. Older patients with DILI exhibited an increasingly predominant cholestatic phenotype across a range of culprit drugs, other than amoxicillin-clavulanate, with increased non–liver-related mortality and require a different approach to predict outcome. The oldest DILI patients exhibited a particular phenotype with more severe DILI episodes and need to be considered when stratifying older DILI populations. | es |
dc.format | application/pdf | es |
dc.format.extent | 12 p. | es |
dc.language.iso | eng | es |
dc.publisher | Wiley | es |
dc.relation.ispartof | Clinical Pharmacology & Therapeutics, 109 (4), 1147-1158. | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Liver injury | es |
dc.subject | Drug-Induced | es |
dc.subject | Older Patients | es |
dc.title | Clinical characteristics and outcome of drug-induced liver injury in the older patients: from the young-old to the oldest-old | es |
dc.type | info:eu-repo/semantics/article | es |
dcterms.identifier | https://ror.org/03yxnpp24 | |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Medicina | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Biología Celular | es |
dc.relation.publisherversion | http://doi.org/10.1002/cpt.2108 | es |
dc.identifier.doi | 10.1002/cpt.2108 | es |
dc.journaltitle | Clinical Pharmacology & Therapeutics | es |
dc.publication.volumen | 109 | es |
dc.publication.issue | 4 | es |
dc.publication.initialPage | 1147 | es |
dc.publication.endPage | 1158 | es |